Safety & Side Effects
Across its published reports, amycretin's side-effect profile is gastrointestinal, dose-related and mostly mild to…
Mostly the gut, with class questions to watch
Across its published reports, amycretin's side-effect profile is gastrointestinal, dose-related and mostly mild to moderate. In the oral first-in-human trial every one of the 364 events was mild or moderate; in the subcutaneous early-phase trial the majority were mild to moderate, which is a weaker statement and worth reading precisely. The 2026 phase 2 papers describe the same pattern.
This unit separates what was measured from what was only screened for, and is honest that the long-term safety record for amycretin does not exist yet. One rule runs through it: serious-adverse-event percentages here include placebo recipients in their denominators, so this unit gives counts.
Key terms
The gut side effects
The most common of amycretin's observed side effects were gastrointestinal; for the oral first-in-human trial the sponsor names them as mainly nausea and vomiting, plus decreased appetite. In the oral phase 1, all adverse events were mild or moderate and GI events made up about half. In the subcutaneous trial, gastrointestinal events were again the most common treatment-emergent adverse events and the majority were mild to moderate, a weaker statement than "all" and worth reading precisely. In the oral phase 2 cohort the dose relationship is visible directly: gastrointestinal events in 14 of 54 participants on 6 mg, 21 of 51 on 25 mg and 24 of 51 on 50 mg, against seven of 30 on placebo.
Read what that chart is: the only published amycretin adverse-event series, and it tracks dose, not time. No published report describes how nausea behaves week by week in an amycretin trial, so this course gives no time course for it.
The reassuring part is that the subcutaneous abstract reports the majority of events as mild to moderate and resolving by the end of the study. The unreassuring part is that they are dose-related, and because amycretin engages two gastric-slowing mechanisms, the burden could be prominent at higher doses, exactly where the biggest weight figures came from. The independent network analysis also found gastrointestinal events particularly frequent for oral amycretin.
AdvancedWhy two gastric-slowing arms can add GI burden
Both GLP-1 and amylin slow gastric emptying, so a co-agonist engages that mechanism twice. This is the flip side of the additive-benefit story: the same actions that add weight loss also partly add nausea and fullness. In the oral first-in-human trial every event was mild or moderate and in the subcutaneous trial the majority were, which is a weaker statement. Whether the higher-dose GI burden is tolerable for most people over the long term is an open question phase 3 must answer.